At Hisun USA, our goal is to create a broad portfolio of generics through leveraging the diverse and expansive capabilities of our parent company while actively seeking to acquire products, technologies or companies with strategic value in the US market. Hisun holds 21 pending ANDAs with many more under development. We have been marketing ANDA product in US market for over one year and are planning to launch more ANDA products in the coming months. With a growing pipeline of oral solid dosage and injectable products, we are committed to develop and supply products through our extensive resources and experience:

  • Focus on market and technologically differentiated products
  • Vertically integrated with a well-established API business
  • Proven biopharmaceutical & biosimilar development track record

For more information, please contact:

John Kline
Vice President, National Accounts
Office: 916-705-2747
Email: john.kline@hisunusa.com

Martin Wingerter
Senior Director, National Accounts
Office: 214-676-3852
Email: martin.wingerter@hisunusa.com

Hisun Pharmaceuticals USA, Inc. 
200 Crossing Blvd, 2nd Floor 
Bridgewater, NJ 08807 

For Returns: returns@hisunusa.com
For Customer Service: customerservice@hisunusa.com

To report SUSPECTED ADVERSE REACTIONS and product quality related issues, contact Hisun Pharmaceuticals USA, Inc. at 1-855-554-4786